SYRE vs. PCRX, MIRM, COLL, BLTE, PRTA, MNKD, GYRE, IRWD, VRNA, and ABCL
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Pacira BioSciences (PCRX), Mirum Pharmaceuticals (MIRM), Collegium Pharmaceutical (COLL), Belite Bio (BLTE), Prothena (PRTA), MannKind (MNKD), Gyre Therapeutics (GYRE), Ironwood Pharmaceuticals (IRWD), Verona Pharma (VRNA), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical preparations" industry.
Spyre Therapeutics (NASDAQ:SYRE) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations.
In the previous week, Spyre Therapeutics had 5 more articles in the media than Pacira BioSciences. MarketBeat recorded 8 mentions for Spyre Therapeutics and 3 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.93 beat Spyre Therapeutics' score of 0.76 indicating that Pacira BioSciences is being referred to more favorably in the news media.
Spyre Therapeutics presently has a consensus target price of $43.17, suggesting a potential upside of 14.20%. Pacira BioSciences has a consensus target price of $47.40, suggesting a potential upside of 53.80%. Given Pacira BioSciences' higher possible upside, analysts clearly believe Pacira BioSciences is more favorable than Spyre Therapeutics.
80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 6.2% of Spyre Therapeutics shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Pacira BioSciences has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
Pacira BioSciences received 799 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 71.81% of users gave Pacira BioSciences an outperform vote.
Pacira BioSciences has a net margin of 10.34% compared to Spyre Therapeutics' net margin of 0.00%. Pacira BioSciences' return on equity of 12.98% beat Spyre Therapeutics' return on equity.
Spyre Therapeutics has a beta of 2.93, meaning that its share price is 193% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.
Summary
Pacira BioSciences beats Spyre Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Spyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
